Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.
| Revenue (TTM) | $268.68M |
| Gross Profit (TTM) | $199.11M |
| EBITDA | $38.87M |
| Operating Margin | -49.90% |
| Return on Equity | -35.40% |
| Return on Assets | 3.14% |
| Revenue/Share (TTM) | $7.24 |
| Book Value | $0.77 |
| Price-to-Book | 55.50 |
| Price-to-Sales (TTM) | 6.40 |
| EV/Revenue | 6.7 |
| EV/EBITDA | 55.34 |
| Quarterly Earnings Growth (YoY) | -10.30% |
| Quarterly Revenue Growth (YoY) | -7.60% |
| Shares Outstanding | $37.28M |
| Float | $28.28M |
| % Insiders | 15.47% |
| % Institutions | 58.85% |
Volatility is currently contracting
Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar
INCHEON, Korea--(BUSINESS WIRE)-- #Byooviz--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTIS1 (ranibizumab), and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEA2 (aflibercept), upon full transition of commercialization rights from Biogen back to Samsung Bioepis by the end of 20.
Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an FDA-approved VKC treatment for pediatric patients.
NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the re-launch of VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy indicated for the treatment of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children.
NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair's 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.
MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Harrow, Inc. (Nasdaq: HROW) (“HROW”) has violated the federal securities laws after the company advised that VEVYE revenue of $20.9 million during the first quarter of 2026 was below expectations due to an estimated $8 million gross-to-net reduction associated with new commercial coverage for VEVYE.
Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript
Harrow NASDAQ: HROW executives said the company's first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emphasized that underlying demand for its core ophthalmic products is accelerating.
First Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand growth on track to deliver 2026 revenue of over $100 million Quarterly revenue of $44.2 million, including a non-recurring gross-to-net revenue adjustment connected to new VEVYE commercial coverage, which lowered Q1 revenue by approximately $8 million IHEEZO® unit demand increased 18% year-over-year, with 82% of units from retina accounts TRIESENCE® unit demand more than doubled year-over-year, the sixth consecutive quarter of growth Second Quarter revenue expected between $71 million and $81 million Full-year 2026 revenue guidance reaffirmed at $350 million to $365 million Cash and cash equivalents of $94.6 million as of March 31, 2026 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
